Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0P5QU
|
|||
Former ID |
DIB020074
|
|||
Drug Name |
IS1
|
|||
Synonyms |
N-{2-Furan-2-yl-1-[(pyridin-3-ylmethyl)-carbamoyl]-vinyl}-benzamide; IS1; AC1MFOLV; SMR000176552; Salor-int l253618-1ea; MLS000551960; GTPL8517; CHEMBL1499206; SCHEMBL10092076; MolPort-000-526-523; HMS2374A20; ZINC4892255; AKOS000531713; BAS 01151561; ACM324562018; ST053578; SR-01000425582; SR-01000425582-1; N-[(Z)-1-furan-2-yl-3-oxo-3-(pyridin-3-ylmethylamino)prop-1-en-2-yl]benzamide; N~1~-((Z)-2-(2-furyl)-1-{[(3-pyridylmethyl)amino]carbonyl}-1-ethenyl)benzamide
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL
|
|||
Formula |
C20H17N3O3
|
|||
Canonical SMILES |
C1=CC=C(C=C1)C(=O)NC(=CC2=CC=CO2)C(=O)NCC3=CN=CC=C3
|
|||
InChI |
1S/C20H17N3O3/c24-19(16-7-2-1-3-8-16)23-18(12-17-9-5-11-26-17)20(25)22-14-15-6-4-10-21-13-15/h1-13H,14H2,(H,22,25)(H,23,24)/b18-12-
|
|||
InChIKey |
ANTQNDKESCDJPE-PDGQHHTCSA-N
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Prokineticin receptor-1 (PROKR1) | Target Info | Agonist | [2] |
Reactome | Peptide ligand-binding receptors | |||
G alpha (q) signalling events | ||||
WikiPathways | Gastrin-CREB signalling pathway via PKC and MAPK | |||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8517). | |||
REF 2 | Discovery and cardioprotective effects of the first non-Peptide agonists of the G protein-coupled prokineticin receptor-1. PLoS One. 2015 Apr 1;10(4):e0121027. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.